Intra-operative Radiotherapy For Breast Cancer Women After NSM

Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer After Nipple-sparing Mastectomy

The role of NSM is still controversial, mainly because of concern about the oncologic safety of the nipple-areola complex (NAC).INTRABEAM (Carl Zeiss, Oberkochen, Germany) is the most widely used mobile intraoperative radiotherapy (IORT) device to date. This study aims to assess the value of the INTRABEAM system for breast cancer.

Despite the advancement and increasing use of nipple-sparing mastectomy (NSM) is still carried out in a portion of breast cancer patients. However, the role of NSM is still controversial, mainly because of concern about the oncologic safety of the nipple-areola complex (NAC). Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.INTRABEAM (Carl Zeiss, Oberkochen, Germany) is the most widely used mobile intraoperative radiotherapy (IORT) device to date. This study aims to broaden the application of the INTRABEAM system for breast cancer, investigating the feasibility of INTRABEAM IORT in NSM with breast reconstruction.

Inclusion Criteria:

• Tumor diameter ≤3 cm
• Tumor from the papilla>2cm
• Low grade ductal carcinoma in situ
• Candidate for breast-conserving surgery
• Must have undergone lumpectomy with negative margins or minimal margin involvement
• Currently undergoing re-excision of the biopsy cavity and/or sentinel lymph node biopsy or axillary lymph node dissection
• No evidence of metastatic disease
• Informed consent

Exclusion Criteria:

• No informed consent
• Tumor size > 3 cm
• Tumor from the papilla≤2cm
• Intermediate or high grade ductal carcinoma in situ
• Invasive carcinoma
• No indication for a boost